In particular, TCR-based therapeutics hold great promise to improve immunotherapies, as T cells are key players in adaptive immune response leading to curative effects in…
Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…
Onur Boyman, an immunologist working at the University Hospital Zurich and UZH, has joined forces with Andreas Katopodis to establish Anaveon, a BaseLaunch participant. Aiming to translate…